Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
- Eisai to Form Alliance with University College London for Drug Discovery Research
December 18, 2012
- Chugai to Adopt IFRS from FY2013
December 18, 2012
- Takeda Launches Phone Service to Support Patients’ Drug Administration
December 17, 2012
- Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
- AstraZeneca’s Novel RA Drug Fostamatinib Fails to Demonstrate Non-Inferiority to Humira in PIIb Study
December 17, 2012
- Eli Lilly to Conduct Additional Trial of Novel AD Treatment Solanezumab
December 17, 2012
- Eli Lilly to Discontinue One of Three PIII Rheumatoid Arthritis Registration Studies of Tabalumab
December 17, 2012
- Janssen Research & Development Submits NDA for Canagliflozin/Metformin Fixed-Dose Combination in the US
December 17, 2012
- Eisai Concludes Strategic Manufacturing Alliance with Biogen Idec for Contract Manufacturing at Eisai Inc.’s US Plant
December 17, 2012
- Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
- Calls by MRs from Pfizer Japan Left Best Impression at Insurance Pharmacies in October: Nextit Research
December 14, 2012
- ADCETRIS Shows Tolerability in Untreated HL Patients: Takeda
December 14, 2012
- Lyrica, Other Key Products Upbeat in FY2012 Despite NHI Price Revision: Pfizer Japan Pres. Umeda
December 13, 2012
- Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
- Astellas Initiates PIII Study of Oral Renal Anemia Treatment in US, Europe
December 13, 2012
- Importance of Alliances Increasing in Competitive Diabetes Drug Market
December 13, 2012
- About 50% of FLT3-ITD Positive Patients Achieve CRc in PII Study for Quizartinib: Astellas
December 13, 2012
- Kaken Initiates Voluntary Partial Recall of Empynase-P Tablets 18000
December 13, 2012
- UMN Pharma Listed on TSE Mothers, Sets Midterm Plan Target to Be in Black
December 13, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…